首页> 外文期刊>Case Reports in Immunology >Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy
【24h】

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy

机译:白细胞介素-1受体拮抗剂的缺乏:患有晚期炎症性关节炎的案例,用甲氧单闭虫病和对Adalimalab疗法的良好良好的肺牛皮癣

获取原文
       

摘要

DIRA (deficiency of the IL-1Ra) is a rare condition that usually presents in the neonatal period. Patients with DIRA present with systemic inflammation, respiratory distress, joint swelling, pustular rash, multifocal osteomyelitis, and periostitis. Previously, we reported a patient with a novel mutation in IL1RN with a healthy neonatal period, a late-onset of pustular dermatosis, inflammatory arthritis, and excellent response to canakinumab treatment. Herein, we are presenting a new case of late-onset DIRA syndrome, carrying a different mutation and showing different clinical findings. This patient is the first one in the literature with the inflammatory arthritis, nail psoriasis, and onychomycosis and with her remarkable response to monoclonal antibodies. The case responded well and fully recovered after treatment with adalimumab, but not with canakinumab. The DIRA disease can lead to death from multiple organ failures and if recognized early, the treatment with replacement of the deficient protein with biologic agents induces rapid and complete remission. Therefore, clinical symptoms should be learned exactly by the pediatricians, pediatric rheumatologists, and immunologists; and molecular analysis targeting this defect must be performed as early as possible.
机译:DIRA(IL-1RA的缺乏)是一种罕见的条件,通常在新生儿期间出现。患者存在具有全身炎症,呼吸窘迫,关节肿胀,脓疱疹,多焦点骨髓炎和骨膜炎的患者。以前,我们报告了IL1RN中具有新突变的患者,具有健康的新生儿时期,脓疱皮肤病的晚期发作,炎症性关节炎和对Canakinumab治疗的优异反应。在此,我们呈现出晚期染色综合征的新案例,携带不同的突变并显示不同的临床发现。该患者是文献中的第一个,具有炎性关节炎,指甲牛皮癣和甲癣,对单克隆抗体的显着反应。这种情况良好并在用Adalimumab治疗后完全恢复,但不用Canakinumab。 Dia疾病可能导致来自多器官失败的死亡,如果早期识别,用生物剂替代缺乏蛋白质的治疗诱导快速完全缓解。因此,应由儿科医生,儿科风湿病学家和免疫学家完全了解临床症状;靶向该缺陷的分子分析必须尽早进行。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号